NDC-002 is under clinical development by DR.Noah Biotech and currently in Phase I for Dementia. According to GlobalData, Phase I drugs for Dementia have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NDC-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NDC-002 overview

NDC-002 is under development for the treatment of stroke and dementia. The drug candidate is developing as a combinatory drug with two agents. It is being developed based on ARK platform. It is administered through oral route.

DR.Noah Biotech overview

DR.Noah Biotech (DR.Noah) is a next-generation pharmaceutical company that develops new drugs based on big data analysis medicine and artificial intelligence technology. DR.Noah is Headquartered in Suwon, Republic of Korea (South Korea).

For a complete picture of NDC-002’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.